Clinical trials: Postmenopausal Osteoporosis, open to volunteers
- Condition Postmenopausal Osteoporosis
- Status Open to volunteers
- Funder type Industry (pharma, biotech, devices)
Postmenopausal Osteoporosis, Low Bone Mass
Study of TST002 Injection in Postmenopausal Women With Osteoporosis or Low Bone Mass
This is a randomized, double-blind, placebo- and active-controlled Phase II study evaluating the efficacy and safety of TST002 injection (a humanized monoclonal antibody) in postmenopausal women with osteoporosis or low bone…
- Trial name
- NCT07806331
- Testing
- Denosumab
- Volunteers
- 110 people
- Sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
Postmenopausal Women With Osteoporosis
A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens
This is a multicenter, randomized, open-label, parallel-controlled Phase II study designed to evaluate the differences in safety among four different dosing regimens of SAL056.
- Trial name
- NCT07579936
- Testing
- SAL056 56.5μg, Intervention Group 1, Intervention Group 2
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Postmenopausal Women With Osteoporosis at High Risk of Fracture
A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®
This study is a multicenter, randomized, double-blind comparative study to valuating the efficacy and safety of QL1206 and Prolia® in postmenopausal women with osteoporosis at high risk of fracture.
- Trial name
- NCT07062978
- Testing
- QL1206, Prolia®
- Where
- China
- Volunteers
- 278 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Postmenopausal Women With Osteoporosis
To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture
The purpose of this study is to evaluate the efficacy and safety of QLG2128 in the treatment of postmenopausal women with osteoporosis and at high risk of fracture.
- Trial name
- NCT06898060
- Testing
- QLG2128, Teriparatide Injection
- Volunteers
- 282 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Menopause, Perimenopausal Disorder
Virtual perI-/Menopause Registry of AusTrALia
13 million (50.7%) Australians are born with ovaries, 14% (~3 million) are currently aged 40-59 yrs, \& all such who live to midlife will experience menopause, defined as >12 months without a period.
- Conditions
- Menopause, Perimenopausal Disorder, Postmenopausal Symptoms, Health Knowledge, Attitudes, Practice
- Trial name
- VITAL (NCT06487130)
- Testing
- N/A Observational Registry
- Where
- Australia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Bespoke Clinical Research